Technicolor limits at the Tevatron

Direct searches for the technicolor particles at the Tevatron collider experiments at {radical}s=1.8 TeV are described. Various color-singlet and color-octet heavy technimeson states are predicted in the recent technicolor models. The topcolor assisted technicolor model predicts new heavy gluon, top-gluon. These new particles, {rho}{sub T}, {omega}{sub T}, {pi}{sub T}, and top-gluon are expected to be produced in high energy p{anti p} collisions if they exist and they are searched in the world highest energy p{anti p} collider experiments, CDF and D0 experiments. In this report, current mass limits for these particles are shown

Search for Technicolor Particles in W+2jet with b-tag Channel at CDF CDF PUB EXOTIC PUBLIC 4428 version 2.2 Search for Technicolor Particles in W+2jet with b-tag Channel at CDF

Abstract. We present a preliminary result from a search for walking technicolor particles using leptonically decayed W plus two jets with at least one b -tag using 109 7 p b ,1 of data taken by the Collider Detector at Fermilab CDF. We search for technipion mass peaks in the invariant mass distribution of the two jet system and technirho mass peaks in the invariant mass distribution of W +2jet system. We do not see any signi cant excess in our search sample, and set 95 con dence level upper limits on the production cross section and exclude a region of the T mass v.s. T mass plane

Long-term safety and efficacy of alogliptin, a DPP-4 inhibitor, in patients with type 2 diabetes: a 3-year prospective, controlled, observational study (J-BRAND Registry)

Introduction Given an increasing use of dipeptidyl peptidase-4 (DPP-4) inhibitors to treat patients with type 2 diabetes mellitus in the real-world setting, we conducted a prospective observational study (Japan-based Clinical Research Network for Diabetes Registry: J-BRAND Registry) to elucidate the safety and efficacy profile of long-term usage of alogliptin.Research design and methods We registered 5969 patients from April 2012 through September 2014, who started receiving alogliptin (group A) or other classes of oral hypoglycemic agents (OHAs; group B), and were followed for 3 years at 239 sites nationwide. Safety was the primary outcome. Symptomatic hypoglycemia, pancreatitis, skin disorders of non-extrinsic origin, severe infections, and cancer were collected as major adverse events (AEs). Efficacy assessment was the secondary outcome and included changes in hemoglobin A1c (HbA1c), fasting blood glucose, fasting insulin and urinary albumin.Results Of the registered, 5150 (group A: 3395 and group B: 1755) and 5096 (3358 and 1738) were included for safety and efficacy analysis, respectively. Group A patients mostly (>90%) continued to use alogliptin. In group B, biguanides were the primary agents, while DPP-4 inhibitors were added in up to ~36% of patients. The overall incidence of AEs was similar between the two groups (42.7% vs 42.2%). Kaplan-Meier analysis revealed the incidence of cancer was significantly higher in group A than in group B (7.4% vs 4.8%, p=0.040), while no significant incidence difference was observed in the individual cancer. Multivariate Cox regression analysis revealed that the imbalanced patient distribution (more elderly patients in group A than in group B), but not alogliptin usage per se, contributed to cancer development. The incidence of other major AE categories was with no between-group difference. Between-group difference was not detected, either, in the incidence of microvascular and macrovascular complications. HbA1c and fasting glucose decreased significantly at the 0.5-year visit and nearly plateaued thereafter in both groups.Conclusions Alogliptin as a representative of DPP-4 inhibitors was safe and durably efficacious when used alone or with other OHAs for patients with type 2 diabetes in the real world setting